How much does capmatinib’s original drug cost?

Capmatinib, a targeted drug produced by Novartis Pharmaceuticals, brings a new treatment strategy to patients with non-small cell lung cancer with mesenchymal epithelial transition (MET) exon 14 skip mutation. As a complement to traditional chemotherapy, it provides patients with more treatment opportunities. However, the price of its original drugs has always been a hot topic of public discussion.

Currently on the market, the Hong Kong and European versions of the original version of capmatinib are the most common. According to recent market data, the price of the Hong Kong version of the drug (200mg*60 tablets) is around 35,000, while the European version (200mg*120 tablets) is around 57,000. However, please note that these prices will fluctuate due to exchange rates and supply and demand. Therefore, patients should refer to the latest quotations from pharmaceutical manufacturers or authoritative institutions when making actual purchases.

Although the Hong Kong version and the European version are different in price, the ingredients and therapeutic effects of the two are exactly the same. When making a choice, patients mainly need to consider their own financial situation and local medical policies. At the same time, in order to ensure the authenticity and therapeutic effect of the medicine, patients should purchase it through formal channels and use it strictly in accordance with doctor's instructions.

It is worth mentioning that for patients with limited financial conditions, generic drugs in Laos provide a more economical option, which undoubtedly brings more hope to patients. According to inquiries, the price of Laos' Lucius version of generic medicine is about 3,500 per box, and the Lao Big Bear version of generic medicine is about more than 3,000 per box. Patients can choose by themselves. These two generic drugs have been approved by the government and are officially marketed drugs. Their quality is guaranteed and patients do not need to worry too much.